Loading patent…
AssigneePhilogen S.P.A.
InventorsLuciano ZARDI, Dario NERI, Barbara CARNEMOLLA, Fredrik NILSSON, Lorenzo TARLI, Laura BORSI, Cornelia HALIN
Estimating the term…
Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-γ (IFN-γ), Tumor Necrosis Factor α (TNFα) or Tissue Factor protein (which may be truncated).
A conjugate of (i) a specific binding member specific for an extracellular matrix component which is present in angiogenesis in pathological lesions, and (ii) a molecule selected from the group consisting of:
A conjugate of (i) a specific binding member specific for an extracellular matrix component which is present in angiogenesis in pathological lesions, and (ii) a molecule which exerts a biocidal or cytotoxic effect on target cells by cellular interaction, characterised in that the specific binding member comprises one or more VH and/or VL domains of antibody L19 and/or competes with antibody L19 for binding to fibronectin ED-B, the amino acid sequences of the VH and VL domains of antibody L19 being disclosed in Pini et al. (1998) J. Biol. Chem. 273:
A nucleic acid encoding a conjugate of:
Dependencies are inferred from the claim text.